2. Immunology/Inflammation
  3. CD20
  4. Ocrelizumab

Ocrelizumab  (Synonyms: 2H7; PRO70769; RG1594)

Cat. No.: HY-P9960 Pureza: ≥99.0%
COA
SDS
Technical Support

Ocrelizumab (Ocrevus) is a humanized anti-CD20 monoclonal antibody. Ocrelizumab can induce B cell depletion and inhibit multiple sclerosis lesions in mice through antibody dependent cytotoxicity (ADCC).

Para uso exclusivo en investigación. No vendemos a pacientes.

No. CAS : 637334-45-3

Tamaño Precio Stock Cantidad
Muestra gratis (100 μg)   Solicite ahora  
1 mg En stock
5 mg En stock
10 mg En stock
50 mg   Obtener un presupuesto  
100 mg   Obtener un presupuesto  

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Ocrelizumab Related Antibodies

Top Publications Citing Use of Products

  • Actividad biológica

  • Pureza y Documentación

  • Referencias

  • Revisión del cliente

Descripciòn

Ocrelizumab (Ocrevus) is a humanized anti-CD20 monoclonal antibody. Ocrelizumab can induce B cell depletion and inhibit multiple sclerosis lesions in mice through antibody dependent cytotoxicity (ADCC)[1][2].
Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity

Human
IC50 & Target

CD20/MS4A1
In Vivo

Ocrelizumab (7.5 mg/kg; once daily; 18 days; s.c. or i.v.) inhibits lesions in multiple sclerosis mice by inducing B cell exhaustion through antibody dependent cytotoxicity (ADCC)[1].
Ocrelizumab (50 μg; repeat administration on days 7, 14, and 21; i.v.) can reduce B and T cells in the blood, lymph nodes, and spleen of C57BL/6 mice[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: HuCD20 mice with chronic DTH-TLS lesions[1].
Dosage: 7.5 mg/kg
Administration: Subcutaneous injection (s.c.) or intravenous injection (i.v.); once daily; 18 days; initiated on Days 63, 70 and 75 post lesion induction
Result: Reduced the number of CD19+ cells and MS like lesions in the spleen and lymph nodes of mice.
Animal Model: C57BL/6 mice [2].
Dosage: 50 μg
Administration: Intravenous injection (i.v.); repeat administration on days 7, 14, and 21
Result: Reduced the total CD19+ B cells and CD4, CD8 T cells in the blood, spleen, and LN.
Ensayo clínico
Gene ID

931  [NCBI]

Accession
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Peso molecular

145.82 kDa

No. CAS
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Ocrelizumab]
Envío

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Almacenamiento

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 kappa
Biological Activity
  • Immobilized CD20/MS4A1 Protein-VLP, Human (HEK293, HY-P78543) can bind Ocrelizumab. The EC50 for this effect is 19.79 ng/mL.
  • Flow Cytometry analysis of Raji cells labelling CD20 (red) with Ocrelizumab (anti-CD20) (HY-P9960). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/200 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
Pureza y Documentación
Referencias
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Ocrelizumab Related Classifications

  • Calculadora de molaridad

  • Calculadora de dilución

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Ocrelizumab637334-45-32H7 PRO70769 RG1594PRO70769PRO 70769PRO-70769RG1594RG 1594RG-1594CD20Humanized antibodyB cell depletionmultiple sclerosisInhibitorinhibitorinhibit

Productos vistos recientemente:

Consulta en línea

Your information is safe with us. * Required Fields.

Nombre del producto

  

Requested Quantity *

Nombre del solicitante *

 

Saludo

Direcciòn del E-mail *

 

Número de teléfono *

Department

 

Nombre de la Organizaciòn *

City

Provincia

Country or Region *

      

Observaciones

Consulta para venta a granel

Inquiry Information

Nombre del producto:
Ocrelizumab
Cat. No.:
HY-P9960
Cantidad:
MCE Japan Authorized Agent:

Revisión del cliente

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Nombre del producto

  

Lot #

Nombre del solicitante *

 

Direcciòn del E-mail *

Número de teléfono

 

Department *

Nombre de la Organizaciòn *

 

Country or Region *

Observaciones

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.